Enwei Pharmaceutical Co., Ltd. Stock

Equities

301331

CNE100005LC7

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-05-16 EDT 5-day change 1st Jan Change
42.33 CNY +0.81% Intraday chart for Enwei Pharmaceutical Co., Ltd. +4.99% +1.98%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 692M 95.75M 130M Sales 2023 785M 109M 148M Capitalization 2.91B 403M 549M
Net income 2022 67M 9.28M 12.63M Net income 2023 86M 11.91M 16.21M EV / Sales 2022 3.2 x
Net cash position 2022 578M 80.04M 109M Net cash position 2023 392M 54.26M 73.87M EV / Sales 2023 3.21 x
P/E ratio 2022
33.4 x
P/E ratio 2023
33.7 x
Employees 1,610
Yield 2022
4.02%
Yield 2023
1.93%
Free-Float 26.25%
More Fundamentals * Assessed data
Dynamic Chart
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023. CI
Enwei Pharmaceutical Co., Ltd. Approves Appointment of Independent Directors and Non-Employee Supervisors CI
Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023. CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Enwei Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares. CI
Enwei Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Certain A Shares of Enwei Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-SEP-2023. CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Enwei Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 23 May 2023 CI
Enwei Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022 CI
Enwei Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022 CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Enwei Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 522.692 million. CI
More news
1 day+0.81%
1 week+4.99%
Current month+2.57%
1 month+10.23%
3 months+33.45%
6 months-4.38%
Current year+1.98%
More quotes
1 week
39.30
Extreme 39.3
42.75
1 month
35.70
Extreme 35.7
42.98
Current year
27.95
Extreme 27.95
42.98
1 year
27.95
Extreme 27.95
51.79
3 years
27.95
Extreme 27.95
60.00
5 years
27.95
Extreme 27.95
60.00
10 years
27.95
Extreme 27.95
60.00
More quotes
Date Price Change Volume
24-05-17 42.33 +0.81% 888,300
24-05-16 41.99 +1.28% 987,700
24-05-15 41.46 -0.58% 1,295,294
24-05-14 41.7 +4.64% 1,416,900
24-05-13 39.85 -1.17% 502,400

End-of-day quote Shenzhen S.E., May 16, 2024

More quotes
Enwei Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of proprietary Chinese medicines and chemical medicines. The Company focuses on gynecological products, pediatric medicines, respiratory medicines and other fields. The Company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules and Danxiong Tongmai granules. Its products are mainly sold through direct sales and e-commerce. The Company principally conducts its businesses in the domestic market.
More about the company
  1. Stock Market
  2. Equities
  3. 301331 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW